Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 36%
Buy 57%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is a synthetic lethality-focused precision medicine oncology company with a strong cash position and multiple clinical and preclinical programs. Recently completed offerings and collaborations, combined with positive early data for darovasertib combination therapies, provide potential validation and competitive advantages against other companies in the market. However, there are risks to the attainment of its price target, including clinical and regulatory failure, as well as potential commercial challenges from competing therapies. Despite these risks, the company's strong cash position and promising combination therapies make it an attractive investment opportunity.

Bears say

IDEAYA Biosciences is facing several challenges as an oncology-focused precision medicine company, including the potential for regulatory execution setbacks and competition from similar companies with new technologies. Additionally, there is a high risk that sales from their clinical-stage product candidates, particularly darovasertib and IDE397, may not meet expectations due to the high unmet need in the market. These risks, along with potential dilutive financing, may negatively impact the company's financials in the future.

IDYA has been analyzed by 14 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 57% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 14 analysts, IDYA has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.